Drug Profile


Alternative Names: 1014802; [14C]-BIIB 074; BIIB 074; CNV 1014802; GSK1014802; Vixotrigine

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Biogen; GlaxoSmithKline
  • Class Analgesics; Neuropsychotherapeutics; Pyrrolidines; Small molecules
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Trigeminal neuralgia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Neuropathic pain; Trigeminal neuralgia

Highest Development Phases

  • Phase III Trigeminal neuralgia
  • Phase II Erythromelalgia; Neuropathic pain
  • Discontinued Bipolar disorders

Most Recent Events

  • 06 Mar 2017 Phase-III clinical trials in Trigeminal neuralgia in Hungary (PO) (EudraCT2016-002473-35)
  • 14 Feb 2017 Phase-III clinical trials in Trigeminal neuralgia in Austria (PO) (EudraCT2016-001449-16)
  • 01 Feb 2017 Biogen completes a phase I pharmacokinetics trial for Trigeminal neuralgia (In volunteers) in United Kingdom (PO) (NCT02831517)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top